Influenza-specific antibody-dependent cellular cytotoxicity: Toward a universal influenza vaccine

Journal of Immunology

Volumn 193, Issue 2, 2014, Pages 469-475

  Jegaskanda, Sinthujan ^a   Reading, Patrick C ^a,b   Kent, Stephen J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; CROSS REACTION; FLOW CYTOMETRY; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N7; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; VIRUS IMMUNITY;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOGLOBULIN G; INFLUENZA VACCINES; INFLUENZA, HUMAN; MODELS, IMMUNOLOGICAL; ORTHOMYXOVIRIDAE;

EID: 84904263611     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400432     Document Type: Review

References (78)

1. Molinari, N. A., I. R. Ortega-Sanchez, M. L. Messonnier, W. W. Thompson, P. M. Wortley, E. Weintraub, and C. B. Bridges. 2007. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25: 5086-5096. (Pubitemid 46879994)
2. World Health Organization, Influenza (Seasonal) Fact Sheet No. 211, March 2014. Available at: http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed: June 12, 2014.
3. Centers for Disease Control and Prevention (CDC). 2013. Estimated influenza illnesses and hospitalizations averted by influenza vaccination - United States, 2012-13 influenza season. MMWR Morb. Mortal. Wkly. Rep. 62: 997-1000.
4. Tricco, A. C., A. Chit, C. Soobiah, D. Hallett, G. Meier, M. H. Chen, M. Tashkandi, C. T. Bauch, and M. Loeb. 2013. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 11: 153.
5. Park, S. J., E. H. Kim, P. N. Pascua, H. I. Kwon, G. J. Lim, A. Decano, S. M. Kim, M. K. Song, E. C. Shin, and Y. K. Choi. 2014. Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models. J. Gen. Virol. 95: 793-798.
6. Hung, I. F., K. K. To, C. K. Lee, K. L. Lee, W. W. Yan, K. Chan, W. M. Chan, C. W. Ngai, K. I. Law, F. L. Chow, et al. 2013. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 144: 464-473.
7. Hurt, A. C., Y. M. Deng, J. Ernest, N. Caldwell, L. Leang, P. Iannello, N. Komadina, R. Shaw, D. Smith, D. E. Dwyer, et al. 2011. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010. Euro Surveill. 16(3).
8. Hurt, A. C., T. Chotpitayasunondh, N. J. Cox, R. Daniels, A. M. Fry, L. V. Gubareva, F. G. Hayden, D. S. Hui, O. Hungnes, A. Lackenby, et al; WHO Consultation on Pandemic Influenza A (H1N1) 2009 Virus Resistance to Antivirals. 2012. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect. Dis. 12: 240-248.
9. Knipe, D. M., and P. M. Howley. 2006. Fields Virology. Lippincott Williams & Wilkins, Philadelphia.
10. Yap, K. L., G. L. Ada, and I. F. McKenzie. 1978. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 273: 238-239. (Pubitemid 8331715)
11. Lukacher, A. E., V. L. Braciale, and T. J. Braciale. 1984. In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J. Exp. Med. 160: 814-826. (Pubitemid 14074780)
12. Weinfurter, J. T., K. Brunner, S. V. Capuano, III, C. Li, K. W. Broman, Y. Kawaoka, and T. C. Friedrich. 2011. Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog. 7: e1002381.
13. Sridhar, S., S. Begom, A. Bermingham, K. Hoschler, W. Adamson, W. Carman, T. Bean, W. Barclay, J. J. Deeks, and A. Lalvani. 2013. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19: 1305-1312.
14. McMichael, A. J., F. M. Gotch, G. R. Noble, and P. A. Beare. 1983. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 309: 13-17. (Pubitemid 13062888)
15. Quiñones-Parra, S., E. Grant, L. Loh, T. H. Nguyen, K. A. Campbell, S. Y. Tong, A. Miller, P. C. Doherty, D. Vijaykrishna, J. Rossjohn, et al. 2014. Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities. Proc. Natl. Acad. Sci. USA 111: 1049-1054.
16. Valkenburg, S. A., S. Quiñones-Parra, S. Gras, N. Komadina, J. McVernon, Z. Wang, H. Halim, P. Iannello, C. Cole, K. Laurie, et al. 2013. Acute emergence and reversion of influenza A virus quasispecies within CD8+ T cell antigenic peptides. Nat. Commun. 4: 2663.
17. Wiley, D. C., I. A. Wilson, and J. J. Skehel. 1981. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289: 373-378. (Pubitemid 11135143)
18. Caton, A. J., G. G. Brownlee, J. W. Yewdell, and W. Gerhard. 1982. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31: 417-427. (Pubitemid 13178866)
19. Potter, C. W., and J. S. Oxford. 1979. Determinants of immunity to influenza infection in man. Br. Med. Bull. 35: 69-75. (Pubitemid 9096975)
20. Hobson, D., R. L. Curry, A. S. Beare, and A. Ward-Gardner. 1972. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.) 70: 767-777.
21. Dreyfus, C., N. S. Laursen, T. Kwaks, D. Zuijdgeest, R. Khayat, D. C. Ekiert, J. H. Lee, Z. Metlagel, M. V. Bujny, M. Jongeneelen, et al. 2012. Highly conserved protective epitopes on influenza B viruses. Science 337: 1343-1348.
22. Corti, D., J. Voss, S. J. Gamblin, G. Codoni, A. Macagno, D. Jarrossay, S. G. Vachieri, D. Pinna, A. Minola, F. Vanzetta, et al. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333: 850-856.
23. Ekiert, D. C., R. H. Friesen, G. Bhabha, T. Kwaks, M. Jongeneelen, W. Yu, C. Ophorst, F. Cox, H. J. Korse, B. Brandenburg, et al. 2011. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333: 843-850.
24. Brandenburg, B., W. Koudstaal, J. Goudsmit, V. Klaren, C. Tang, M. V. Bujny, H. J. Korse, T. Kwaks, J. J. Otterstrom, J. Juraszek, et al. 2013. Mechanisms of hemagglutinin targeted influenza virus neutralization. PLoS ONE 8: e80034.
25. Ekiert, D. C., G. Bhabha, M. A. Elsliger, R. H. Friesen, M. Jongeneelen, M. Throsby, J. Goudsmit, and I. A. Wilson. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-251.
26. Krammer, F., R. Hai, M. Yondola, G. S. Tan, V. H. Leyva-Grado, A. B. Ryder, M. S. Miller, J. K. Rose, P. Palese, A. García-Sastre, and R. A. Albrecht. 2014. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J. Virol. 88: 3432-3442.
27. Eggink, D., P. H. Goff, and P. Palese. 2014. Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. J. Virol. 88: 699-704.
28. Krammer, F., N. Pica, R. Hai, I. Margine, and P. Palese. 2013. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87: 6542-6550.
29. O'Brien, K. B., T. E. Morrison, D. Y. Dundore, M. T. Heise, and S. Schultz-Cherry. 2011. A protective role for complement C3 protein during pandemic 2009 H1N1 and H5N1 influenza A virus infection. PLoS ONE 6: e17377.
30. Ohta, R., Y. Torii, M. Imai, H. Kimura, N. Okada, and Y. Ito. 2011. Serum concentrations of complement anaphylatoxins and proinflammatory mediators in patients with 2009 H1N1 influenza. Microbiol. Immunol. 55: 191-198.
31. Huber, V. C., J. M. Lynch, D. J. Bucher, J. Le, and D. W. Metzger. 2001. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 166: 7381-7388. (Pubitemid 32525614)
32. Greenberg, S. B., B. S. Criswell, H. R. Six, and R. B. Couch. 1978. Lymphocyte cytotoxicity to influenza virus-infected cells: response to vaccination and virus infection. Infect. Immun. 20: 640-645. (Pubitemid 8351998)
33. Greenberg, S. B., B. S. Criswell, H. R. Six, and R. B. Couch. 1977. Lymphocyte cytotoxicity to influenza virus-infected cells. II. Requirement for antibody and non-T lymphocytes. J. Immunol. 119: 2100-2106. (Pubitemid 8232112)
34. Hashimoto, G., P. F. Wright, and D. T. Karzon. 1983. Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J. Infect. Dis. 148: 785-794. (Pubitemid 14244263)
35. Hashimoto, G., P. F. Wright, and D. T. Karzon. 1983. Ability of human cord blood lymphocytes to mediate antibody-dependent cellular cytotoxicity against influenza virus-infected cells. Infect. Immun. 42: 214-218. (Pubitemid 13012456)
36. Jegaskanda, S., E. R. Job, M. Kramski, K. Laurie, G. Isitman, R. de Rose, W. R. Winnall, I. Stratov, A. G. Brooks, P. C. Reading, and S. J. Kent. 2013. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J. Immunol. 190: 1837-1848.
37. Mellman, I., T. Koch, G. Healey, W. Hunziker, V. Lewis, H. Plutner, H. Miettinen, D. Vaux, K. Moore, and S. Stuart. 1988. Structure and function of Fc receptors on macrophages and lymphocytes. J. Cell Sci. Suppl. 9: 45-65.
38. Tamm, A., and R. E. Schmidt. 1997. IgG binding sites on human Fc gamma receptors. Int. Rev. Immunol. 16: 57-85. (Pubitemid 28073171)
39. Seidel, U. J., P. Schlegel, and P. Lang. 2013. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front. Immunol. 4: 76.
40. Oliva, A., A. L. Kinter, M. Vaccarezza, A. Rubbert, A. Catanzaro, S. Moir, J. Monaco, L. Ehler, S. Mizell, R. Jackson, et al. 1998. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J. Clin. Invest. 102: 223-231. (Pubitemid 28323849)
41. Stratov, I., A. Chung, and S. J. Kent. 2008. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J. Virol. 82: 5450-5459. (Pubitemid 351705252)
42. Greenberg, S. B., H. R. Six, S. Drake, and R. B. Couch. 1979. Cell cytotoxicity due to specific influenza antibody production in vitro after recent influenza antigen stimulation. Proc. Natl. Acad. Sci. USA 76: 4622-4626. (Pubitemid 9253940)
43. Jegaskanda, S., J. T. Weinfurter, T. C. Friedrich, and S. J. Kent. 2013. Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J. Virol. 87: 5512-5522.
44. Jegaskanda, S., K. L. Laurie, T. H. Amarasena, W. R. Winnall, M. Kramski, R. De Rose, I. G. Barr, A. G. Brooks, P. C. Reading, and S. J. Kent. 2013. Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1. J. Infect. Dis. 208: 1051-1061.
45. Vella, S., G. Rocchi, S. Resta, M. Marcelli, and A. De Felici. 1980. Antibody reactive in antibody-dependent cell-mediated cytotoxicity following influenza virus vaccination. J. Med. Virol. 6: 203-211. (Pubitemid 11138035)
46. Jegaskanda, S., T. H. Amarasena, K. L. Laurie, H. X. Tan, J. Butler, M. S. Parsons, S. Alcantara, J. Petravic, M. P. Davenport, A. C. Hurt, et al. 2013. Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques. J. Virol. 87: 13706-13718.
47. Li, G. M., C. Chiu, J. Wrammert, M. McCausland, S. F. Andrews, N. Y. Zheng, J. H. Lee, M. Huang, X. Qu, S. Edupuganti, et al. 2012. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl. Acad. Sci. USA 109: 9047-9052.
48. Fang, Y., D. Banner, A. A. Kelvin, S. S. Huang, C. J. Paige, S. A. Corfe, K. P. Kane, R. C. Bleackley, T. Rowe, A. J. Leon, and D. J. Kelvin. 2012. Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism. J. Virol. 86: 2229-2238.
49. Crowe, J. E., Jr. 2001. Influence of maternal antibodies on neonatal immunization against respiratory viruses. Clin. Infect. Dis. 33: 1720-1727. (Pubitemid 33044540)
50. Crowe, J. E., Jr., C. Y. Firestone, and B. R. Murphy. 2001. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J. Immunol. 167: 3910-3918. (Pubitemid 32910836)
51. Corti, D., and A. Lanzavecchia. 2013. Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 31: 705-742.
52. DiLillo, D. J., G. S. Tan, P. Palese, and J. V. Ravetch. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgR interactions for protection against influenza virus in vivo. Nat. Med. 20: 143-151.
53. Friesen, R. H., P. S. Lee, E. J. Stoop, R. M. Hoffman, D. C. Ekiert, G. Bhabha, W. Yu, J. Juraszek, W. Koudstaal, M. Jongeneelen, et al. 2014. A common solution to group 2 influenza virus neutralization. Proc. Natl. Acad. Sci. USA 111: 445-450.
54. Smalls-Mantey, A., N. Doria-Rose, R. Klein, A. Patamawenu, S. A. Migueles, S. Y. Ko, C.W. Hallahan, H. Wong, B. Liu, L. You, et al. 2012. Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J. Virol. 86: 8672-8680.
55. Dawood, F. S., S. Jain, L. Finelli, M. W. Shaw, S. Lindstrom, R. J. Garten, L. V. Gubareva, X. Xu, C. B. Bridges, and T. M. Uyeki; Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. 2009. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360: 2605-2615.
56. Garten, R. J., C. T. Davis, C. A. Russell, B. Shu, S. Lindstrom, A. Balish, W. M. Sessions, X. Xu, E. Skepner, V. Deyde, et al. 2009. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325: 197-201.
57. Kelly, H., and K. Grant. 2009. Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill. 14(31). 14.
58. Chowell, G., S. M. Bertozzi, M. A. Colchero, H. Lopez-Gatell, C. Alpuche-Aranda, M. Hernandez, and M. A. Miller. 2009. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N. Engl. J. Med. 361: 674-679.
59. Hancock, K., V. Veguilla, X. Lu, W. Zhong, E. N. Butler, H. Sun, F. Liu, L. Dong, J. R. DeVos, P. M. Gargiullo, et al. 2009. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 361: 1945-1952.
60. Manicassamy, B., R. A. Medina, R. Hai, T. Tsibane, S. Stertz, E. Nistal-Villán, P. Palese, C. F. Basler, and A. García-Sastre. 2010. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog. 6: e1000745.
61. O'Donnell, C. D., A. Wright, L. N. Vogel, C. J. Wei, G. J. Nabel, and K. Subbarao. 2012. Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus. J. Virol. 86: 8625-8633.
62. Laurie, K. L., L. A. Carolan, D. Middleton, S. Lowther, A. Kelso, and I. G. Barr. 2010. Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model. J. Infect. Dis. 202: 1011-1020.
63. Carter, D. M., C. E. Bloom, E. J. Nascimento, E. T. Marques, J. K. Craigo, J. L. Cherry, D. J. Lipman, and T. M. Ross. 2013. Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza virus. J. Virol. 87: 1400-1410.
64. LaMere, M. W., H. T. Lam, A. Moquin, L. Haynes, F. E. Lund, T. D. Randall, and D. A. Kaminski. 2011. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J. Immunol. 186: 4331-4339.
65. Lamere, M. W., A. Moquin, F. E. Lee, R. S. Misra, P. J. Blair, L. Haynes, T. D. Randall, F. E. Lund, and D. A. Kaminski. 2011. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J. Virol. 85: 5027-5035.
66. Wraith, D. C., A. E. Vessey, and B. A. Askonas. 1987. Purified influenza virus nucleoprotein protects mice from lethal infection. J. Gen. Virol. 68: 433-440. (Pubitemid 17007830)
67. Ulmer, J. B., J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. L. Felgner, V. J. Dwarki, S. H. Gromkowski, R. R. Deck, C. M. DeWitt, A. Friedman, et al. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749. (Pubitemid 23114660)
68. Carragher, D. M., D. A. Kaminski, A. Moquin, L. Hartson, and T. D. Randall. 2008. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J. Immunol. 181: 4168-4176.
69. Virelizier, J. L., A. C. Allison, J. S. Oxford, and G. C. Schild. 1977. Early presence of ribonucleoprotein antigen on surface of influenza virus-infected cells. Nature 266: 52-54. (Pubitemid 8050009)
70. Yewdell, J. W., E. Frank, and W. Gerhard. 1981. Expression of influenza A virus internal antigens on the surface of infected P815 cells. J. Immunol. 126: 1814-1819. (Pubitemid 11120964)
71. Bodewes, R., M. M. Geelhoed-Mieras, J. Wrammert, R. Ahmed, P. C. Wilson, R. A. Fouchier, A. D. Osterhaus, and G. F. Rimmelzwaan. 2013. In vitro assessment of the immunological significance of a human monoclonal antibody directed to the influenza A virus nucleoprotein. Clin. Vaccine Immunol. 20: 1333-1337.
72. Isitman, G., A. W. Chung, M. Navis, S. J. Kent, and I. Stratov. 2011. Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology 412: 110-116.
73. Wren, L. H., A. W. Chung, G. Isitman, A. D. Kelleher, M. S. Parsons, J. Amin, D. A. Cooper, I. Stratov, M. Navis, and S. J. Kent; ADCC study collaboration investigators. 2013. Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 138: 116-123.
74. Laidlaw, B. J., V. Decman, M. A. Ali, M. C. Abt, A. I. Wolf, L. A. Monticelli, K. Mozdzanowska, J. M. Angelosanto, D. Artis, J. Erikson, and E. J. Wherry. 2013. Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity. PLoS Pathog. 9: e1003207.
75. El Bakkouri, K., F. Descamps, M. De Filette, A. Smet, E. Festjens, A. Birkett, N. Van Rooijen, S. Verbeek, W. Fiers, and X. Saelens. 2011. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186: 1022-1031.
76. Srivastava, V., Z. Yang, I. F. Hung, J. Xu, B. Zheng, and M. Y. Zhang. 2013. Identification of dominant antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin antigen of pandemic H1N1 influenza virus. J. Virol. 87: 5831-5840.
77. Tomaras, G. D., G. Ferrari, X. Shen, S. M. Alam, H. X. Liao, J. Pollara, M. Bonsignori, M. A. Moody, Y. Fong, X. Chen, et al. 2013. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc. Natl. Acad. Sci. USA 110: 9019-9024.
78. Haynes, B. F., P. B. Gilbert, M. J. McElrath, S. Zolla-Pazner, G. D. Tomaras, S. M. Alam, D. T. Evans, D. C. Montefiori, C. Karnasuta, R. Sutthent, et al. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366: 1275-1286.